Quarterly ResultMay 6, 2026, 07:33 AM
Medline Q1 Net Sales $7.4B, Net Income $239M; Raises FY26 Sales Guidance
AI Summary
Medline reported its first quarter 2026 operating results, with net sales increasing 10.7% to $7.4 billion, driven by new customer implementations and existing customer growth. Despite strong sales, net income decreased 25.8% to $239 million and Adjusted EBITDA fell 10.6% to $776 million, primarily due to higher costs of goods sold (including tariffs) and increased operating expenses. The company, however, expressed confidence in its performance by raising its full-year 2026 Organic Sales growth guidance to 8.5%-9.5%.
Key Highlights
- Medline raised full-year 2026 Organic Sales growth guidance to 8.5%-9.5% from 8%-9%.
- Q1 2026 net sales increased 10.7% to $7.4 billion, up from $6.6 billion in Q1 2025.
- Q1 2026 net income decreased 25.8% to $239 million, compared to $322 million in Q1 2025.
- Q1 2026 Adjusted EBITDA decreased 10.6% to $776 million, down from $868 million in Q1 2025.
- Diluted earnings per share were $0.16, and Adjusted Diluted EPS were $0.33.
- Medline Brand segment net sales grew 6.2% to $3.465 billion.
- Supply Chain Solutions segment net sales increased 15.0% to $3.887 billion.
- Net cash provided by operating activities was $412 million, a 39.6% decrease from Q1 2025.